Intellia Therapeutics (NASDAQ: NTLA)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Intellia Therapeutics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Intellia Therapeutics Company Info
Intellia Therapeutics, Inc. Common Stock
News & Analysis
These CRISPR stocks could be big winners for patient investors.
Investors are reacting negatively to the company's Q2 update.
Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.
A recent legal ruling raises an important question about Intellia Therapeutics' path forward.
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.
More progress in the pipeline has investors bullish on the company's shares.
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/29/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
NTLA earnings call for the period ending October 3, 2021.
NTLA earnings call for the period ending June 30, 2021.
NTLA earnings call for the period ending March 31, 2021.
NTLA earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.